Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 645257 | https://doi.org/10.1155/2013/645257

Jiaa Park, Yong Chool Boo, "Isolation of Resveratrol from Vitis Viniferae Caulis and Its Potent Inhibition of Human Tyrosinase", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 645257, 11 pages, 2013. https://doi.org/10.1155/2013/645257

Isolation of Resveratrol from Vitis Viniferae Caulis and Its Potent Inhibition of Human Tyrosinase

Academic Editor: Senthamil R. Selvan
Received02 Nov 2012
Revised27 Dec 2012
Accepted05 Jan 2013
Published12 Feb 2013


Tyrosinase (TYR) catalyzes rate-limiting reactions of cellular melanin synthesis, and its inhibitors are of commercial interest as potential skin whitening agents. However, the limited availability of human TYR makes the screening of TYR inhibitors difficult. To overcome this hurdle, we transformed nonmelanocytic human embryonic kidney (HEK) 293 cells to express human TYR constitutively. Using these cells as a source of human TYR, the ethanolic extracts of 52 medicinal plants grown in Korea were tested for human TYR activity, and the extract of Vitis Viniferae Caulis (dried stems of the grape tree, Vitis vinifera L.) was found to inhibit human TYR activity potently. An active compound was isolated from this extract by solvent fractionation followed by liquid column chromatography and identified as resveratrol by spectroscopic and chromatographic analyses. Resveratrol was determined to be a highly potent inhibitor of human TYR ( μg mL−1) as compared with p-coumaric acid ( μg mL−1) and arbutin ( μg mL−1) and inhibited melanin synthesis by human epidermal melanocytes at subtoxic concentrations. This study suggests that resveratrol and resveratrol-containing extracts of Vitis Viniferae Caulis have a potential use as skin whitening agents.

1. Introduction

Skin color is a major contributor to human beauty and attractiveness [1]. The color of skin is determined by the composition and distribution of various chromophores, such as melanin, hemoglobin, bilirubin, and carotenoids. Melanin is the major dark pigment found in skin, hair, and eyes and provides protection against harmful ultraviolet radiation that can cause photoageing and photocarcinogenesis [2]. In fact, the incidence of skin cancer was reduced by artificially enhancing melanin synthesis in mice [3]. Furthermore, the frequency of malignant melanoma is lower in dark-skinned people [4]. However, excessive melanin deposition can cause aesthetic skin problems, such as melasma, freckles, and senile lentigines. The cosmetic relevance of melanin in skin has prompted the research and development of cosmeceuticals that inhibit melanin synthesis. Although various melanogenesis inhibitors, such as arbutin, have been incorporated into cosmetics to control unwanted skin pigmentation [5, 6], their efficacies remain controversial.

Melanocytes at the stratum basale of the epidermis synthesize melanin [7], and a group of melanogenic enzymes are involved in the synthesis of melanin in melanosomes [8]. Tyrosinase (TYR, monophenol, dihydroxyphenylalanine:oxygen oxidoreductase, EC catalyzes the initial oxidations of L-tyrosine and L-3,4-dihydroxyphenylalanine (DOPA) to DOPA quinone, which conjugates with cysteine or glutathione to produce 5-S-cysteinyl DOPA and glutathionyl DOPA, respectively, and these conjugates in turn are progressively polymerized to the reddish-yellow pheomelanin. The oxidation of DOPA quinone to DOPA chrome without conjugation to thiol compounds leads to the synthesis of the brownish-black eumelanin. Melanin-carrying melanosomes are then transferred via dendrites to neighboring keratinocytes in the epidermis [9]. Because TYR is the rate-limiting enzyme of the melanogenic pathway, it has been a major target for the control of unwanted skin pigmentation, and as a result, numerous agents have been found to inhibit TYR expression or activity [5, 6, 1012].

In many previous studies, presumably because of availability problems, mushroom TYR has been used instead of human TYR, for the screening of potential skin whitening agents [13, 14]. However, this approach is problematic because the biochemical properties of human and mushroom TYRs are quite different [15, 16]. In particular, many compounds inhibit these enzymes to markedly different extents [17, 18], and therefore, human TYR is essential for accurate screening. To meet this demand, we recently established a human embryonic kidney (HEK) 293-TYR cell line to provide human TYR. This cell line was generated by the stable transfection of nonmelanocytic HEK293 cells with a plasmid that encodes human TYR [19]. These transformed cells proliferated rapidly and expressed the active form of human TYR constitutively. Furthermore, lysates of these cells were used successfully in our recent studies [20].

The aims of the present study were to screen for plant extracts that inhibit human TYR and to isolate and identify the compound in the selected extract. Taking advantage of the established HEK293-TYR cell line as a source of human TYR, extracts of various medicinal plants grown in Korea were subjected to primary screening assays against human TYR. Of the 52 plant extracts tested, the extract of Vitis Viniferae Caulis (VVC) was found to inhibit human TYR activity potently. Thus, this study was focused on VVC extract.

2. Materials and Methods

2.1. Plant Extracts

Ethanolic extracts of medicinal plants used in the initial screening assays were purchased from the Plant Extract Bank of Korea (Daejeon, Republic of Korea) (http://extract.pdrc.re.kr/). Yields of extracts are shown in Table 1.

Extract numberMedicinal plantsCatalogue numberYield of extract
(% dry weight)

1Acanthopanacis CortexCA03-0212.86
2Adenophorae RadixCA01-0981.60
3Akebiae CaulisCA02-0305.84
4Alismatis RhizomaCA04-0644.80
5Angelicae Tenuissimae RadixCA02-01410.00
6Arisaematis RhizomaCA03-0052.60
7Artemisiae Apiaceae HerbaCA03-0741.14
8Artemisiae Iwayomogii HerbaCA04-0363.33
9Aurantii Nobilis PericarpiumCA03-06819.69
10Bambusae Caulis in TaeniamCA03-0553.17
11Bambusae FoliumCA03-0574.36
12Benincasae SemenCA04-0107.12
13Biotae Orientalis FoliumCA03-0766.22
14Biotae Orientalis Folium (Roasted)CA03-0776.84
15Cartami SemenCA04-08612.74
16Castaneae SemenCA01-0071.29
17Chaenomelis FructusCA01-0513.17
18Chrisanthemi Sibirici HerbaCA01-0173.53
19Cirsii RadixCA02-0255.00
20Cnidii RhizomaCA03-0704.73
21Crataegi FructusCA02-0412.01
22Cyperi RhizomaCA03-0882.08
23Cyperi RhizomaCA03-0893.60
24Dioscoreae RhizomaCA04-0231.87
25Dioscoreae Rhizoma (Roasted)CA04-0241.85
26Eucommiae Cortex (Roasted)CA01-0416.54
27 Eucommiae FoliumCA01-0392.63
28Eucommiae RamulusCA01-0403.01
29Forsythiae FructusCA02-0755.00
30Gardeniae Fructus (Roasted)CA03-07815.14
31Glycine Semen NigraCA04-0984.50
32Liriopis TuberCA03-0072.90
33Lycopi HerbaCA04-0623.76
34Machili Thunbergii Cortex CA04-0694.75
35Massa Medicata FermentataCA03-0191.10
36Mori RamulusCA04-0283.27
37Nepeta SpicaCA03-0952.38
38Paeoniae Radix Alba (Roasted)CA01-0732.41
39Paeoniae Radix AlbaCA02-0344.67
40Perillae FoliumCA02-0622.47
41Peucedani Japonici RadixCA01-0627.09
42Peucedani RadixCA03-0494.57
43 Pini PollenCA02-0639.70
44Pini RamulusCA04-03022.40
45Platycodi RadixCA04-00517.60
46Polygoni Avicularis HerbaCA04-0742.96
47 PrunusHumilis SemenCA02-08518.00
48Rehmanniae Radix Crudus (Fresh)CA04-0428.69
49Rehmanniae RadixCA01-0087.00
50Santali Alba LignumCA04-0171.31
51 Selaginellae HerbaCA02-0218.88
52 Vitis Viniferae CaulisCA04-0772.90

2.2. Purification and Identification of the Active Compound X (Resveratrol) in VVC

VVC (dried stems of the grape tree, Vitis vinifera L.) was purchased from Jayeoncho (Seoul, Republic of Korea) (http://www.jherb.com/) and extracted in our laboratory. Plant material (200 g) was ground and extracted with 95% (v/v) aqueous ethanol at room temperature. The solution so-obtained was then evaporated under reduced pressure to dryness to produce VVC extract (yield: 4.8%).

VVC extract (8 g) was suspended in water and liquid-liquid partitioned successively with methylene chloride (MC), ethyl acetate (EtOAc), and n-butanol (BuOH), and the solvent fractions obtained were evaporated to dryness. Fraction yields were MC fraction 23%, EtOAc fraction 12% BuOH fraction 9%, and aqueous (H2O) fraction 56%. The EtOAc fraction inhibited human TYR activity most potently.

The EtOAc fraction (2 mg) was dissolved in ethanol and applied to a silica-coated TLC plate (Merck, Darmstadt, Germany) as a long streak. Ascending TLC was run using a mixture of chloroform, methanol, and acetic acid (90 : 10 : 1, v/v/v) as a mobile phase in an airtight container. Separated bands were viewed under a UV lamp. The TLC plate was then divided into 11 horizontal sectors, and the silica of each sector was scraped into 100 μL of 75% ethanol, vortexed, and centrifuged. Supernatants (4 μL) were subjected to TYR assay, and the compound found to inhibit TYR was designated compound X.

The EtOAc fraction (0.9 g) was then subjected to column chromatography to purify compound X. First separation was performed on a Sephadex LH20 column (Pharmacia Fine Chemical Co., Ltd., Uppsala, Sweden) (3 cm × 20 cm) by eluting with MC : methanol (1 : 1). The eluate was monitored at 280 nm and analyzed by TLC. Fractions containing compound X were pooled and evaporated to dryness. This material (0.3 g) was further separated on a YMC-gel ODS-A column (YMC Co. Ltd., Kyoto, Japan) (3 cm × 20 cm) by step gradient elution using 20~60% aqueous methanol. The eluate was monitored at 280 nm and analyzed by TLC. Compound X-containing fractions were combined and evaporated to yield an amorphous powder (52 mg).

2.3. Instrumental Analyses

UV spectrum was recorded on a Shimadzu UV-1650PC spectrophotometer (Shimadzu Corporation, Kyoto, Japan). NMR spectrum was recorded using a 500 MHz Varian Unity INOVA 500 FT-NMR spectrometer (Varian, Inc., Palo Alto, CA, USA) at room temperature. Chemical shifts (δ ppm) are reported relative to tetramethylsilane. HPLC analysis was done using a Gilson HPLC system (Gilson, Inc. Middleton, WI, USA) equipped with a 321 pump and UV/VIS 151 detector. Separation was done on a 5 μm Hector-M C18 column (4.6 mm × 250 mm) (RStech Co. Daejeon, Republic of Korea). The mobile phase consisted of 0.5% formic acid (A) and acetonitrile (B). The gradient was programmed as follows: 0–50 min, a linear gradient from 30 to 100% B; 50–65 min, 100% B; 65–70 min, a linear gradient from 100 to 30% B; 70–80 min, 30% B. The flow rate was 0.6 mL min−1. The UV detector was set at 280 nm. Calibration curves were generated using authentic resveratrol purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.4. Cell Culture and Preparation of Cell Lysates

Human epidermal melanocytes (HEMs), derived from moderately pigmented neonatal foreskins, were obtained from Cascade Biologics (Portland, OR, USA). Cells were grown in Medium 254 supplemented with human melanocyte growth supplement (Cascade Biologics) and antibiotics. HEK293 cells and murine melanoma B16/F10 cells (CRL-6475) were obtained from the American Type Culture Collection (Manassas, VA, USA). HEK 293 cells were transformed into HEK293-TYR cells stably expressing human TYR, as previously described [19]. HEK293 cells, HEK293-TYR cells, and murine melanoma B16/F10 cells were cultured in growth medium (Dulbecco's minimum Eagle's medium (DMEM) containing 10% fetal bovine serum and antibiotics (100 U mL−1 penicillin, 0.1 mg mL−1 streptomycin, and 0.25 µg mL−1 amphotericin B)). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. Cells were lysed in ice-cold lysis buffer (10 mM Tris-Cl, pH 7.4, 120 mM NaCl, 25 mM KCl, 2.0 mM EGTA, 1.0 mM EDTA, and 0.5% Triton X-100 and protease inhibitor cocktail) and centrifuged at 13,000 ×g for 15 min at 4°C to obtain clear supernatants which were used as cell lysates.

2.5. Assay for TYR Activity

In vitro TYR assays were run for human, murine, and mushroom TYRs. The lysates of HEK293-TYR cells were used as a human TYR preparation in most experiments. In some experiments, the lysates of murine B16/F10 cells (Figure 5), HEK293 cells, and HEMs (Figure 6) were used for comparative purposes. Mushroom TYR was purchased from Sigma-Aldrich. The reaction mixture (200 μL) containing either cell lysates (40 μg protein) or mushroom TYR (20 U) and 0.5 mM L-tyrosine, 1 μM DOPA in 100 mM sodium phosphate buffer (pH 6.8) was placed on a 96-well microplate and incubated at 37°C. The formation of DOPA chrome was monitored by measuring absorbance at 490 nm with a BioRad Model 680 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Assays were also run in the absence of TYR enzyme to correct for potential nonenzymatic reactions. Samples and reference inhibitors were included in reaction mixtures at different concentrations.

2.6. Western Blotting

Western blotting of the cell lysates was conducted under a denatured condition as previously described [19, 21]. Primary antibodies for TYR, tyrosinase-related protein 1 (TRP1), tyrosinase-related protein 2 (TRP2), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunoreactive bands were detected using a picoEPD Western Reagent kit (ELPIS-Biotech, Daejeon, Republic of Korea).

2.7. Assay for Melanin Synthesis in HEMs

Melanogenesis in HEMs was determined as previously described [19]. Cells were pretreated with test material for 60 min, and then melanogenesis was stimulated by adding L-tyrosine (1.0 mM). Media were replaced every other day, and cells were cultured for 6 days. Intracellular melanin was extracted using 0.1 M NaOH at 60°C for 60 min, quantified by measuring absorbance at 490 nm, and normalized for protein content using the Bio-Rad DC assay. Cell viabilities were determined using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide.

2.8. Statistical Analysis

Results are presented as the mean ± SE of three or more independent experiments. Significant differences between groups were determined by one-way ANOVA at values of <0.05.

3. Results

The effects of various plant extracts on human TYR activity were determined in vitro using HEK293-TYR cell lysates. The plant extracts tested in the present study are listed in Table 1. In this assay, 100 µg mL−1 of each plant extract was tested. Arbutin was used as a positive reference compound at a concentration of 80 µg mL−1. Of the 52 plant extracts tested, the strongest inhibition of human TYR was exhibited by the extract of Mori Ramulus (number 36) and the next strongest was the extract of VVC (number 52) (Figure 1(a)). For comparative purposes, the effects of the 52 plant extracts on mushroom TYR were also examined (Figure 1(b)). Mori Ramulus extract inhibited mushroom TYR activity strongly, but the other plant extracts, including VVC extract, did not exhibit remarkable inhibition. These results indicate that the extract of VVC contains constituents that preferentially inhibit human TYR. Thus, VVC extract was examined further.

In the next experiment, the VVC extract was tested at different concentrations. As shown in Figure 2(a), the IC50 value of VVC extract was approximately 30 µg mL−1, indicating that the extract itself is a more potent inhibitor of human TYR than arbutin. VVC extract produced turbidity at higher concentrations, making the assay inaccurate.

VVC extract was liquid-liquid partitioned, and solvent fractions were tested for human TYR activity at 10 µg mL−1 (Figure 2(b)). Of the different fractions (MC, EtOAc, BuOH, and aqueous), only the EtOAc fraction exhibited inhibitory effects against human TYR (  µg mL−1), indicating the active compounds were enriched in this fraction. Thus, the EtOAc fraction was further separated by preparatory TLC (Figure 2(c)), and the resulting 11 subfractions were tested for human TYR activity (Figure 2(d)). The results obtained indicated that number 5 fraction most potently inhibited human TYR activity. The major band in this fraction was denoted compound X.

In the next step, compound X was purified from the EtOAc fraction by successive column chromatography on Sephadex LH20 (Figure 3(a)) and ODS-A columns (Figure 3(b)). Elution fractions were monitored by UV absorbance and analyzed by TLC to check for the presence of compound X. Purified compound X was subjected to NMR analysis. 1H- and 13C-NMR spectroscopic data are provided in Table 2. Based on these data and comparison with literature values [22], compound X was identified to be resveratrol. Cochromatography of purified compound X and authentic resveratrol on a TLC plate further verified this identification (Figure 3(c)). A typical HPLC pattern of VVC extract is shown in Figure 4. The content of resveratrol in VVC extract was determined to be 2.1%, indicating that VVC is a rich source of resveratrol.


Assignment 13C 1H

2105.706.562 ( , J = 2.0 Hz)
4102.696.291 ( , J = 2.3 Hz)
6105.706.562 ( , J = 2.0 Hz)
7129.136.902 ( , J = 16.5 Hz)
8129.997.035 ( , J = 16.0 Hz)
2′128.747.435 ( , J = 8.5 Hz)
3′116.436.856 ( , J = 9.0 Hz)
5′116.436.856 ( , J = 9.0 Hz)
6′128.747.433 ( , J = 8.5 Hz)
3-OH8.231 (s)
5-OH8.231 (s)
3′-OH8.491 (s)

The effects of resveratrol on human, murine, and mushroom TYRs were then examined and compared with those of arbutin and p-coumaric acid. p-Coumaric acid has been known as a potent inhibitor of human TYR and of cellular melanogenesis [1820, 23]. In the assays using cell lysates, resveratrol generated an abnormal dose-response curve at high concentrations due to its property producing turbidity in the reaction mixture. However, its IC50 values were accurately determined at low concentration ranges. As shown in Figure 5(a), resveratrol inhibited human TYR activity more strongly (  µg mL−1) than p-coumaric acid (  µg mL−1) and arbutin (  µg mL−1). Resveratrol also inhibited murine TYR activity (  µg mL−1) more strongly than p-coumaric acid (  µg mL−1) and arbutin (  µg mL−1) (Figure 5(b)). Resveratrol had much smaller effect on mushroom TYR activity (Figure 5(c)) than on human and murine TYRs (Figures 5(a) and 5(b)).

TYR protein synthesized as a de novo form goes through an extensive process of posttranslational modifications to reach a fully matured active form in HEMs [24]. For example, N-glycosylation of TYR is critical for protein folding and activity [25]. To examine whether the TYR expressed in nonmelanocytic HEK293-TYR cells can be fully matured, the lysates of HEK293-TYR cells and HEMs were compared by western blotting and activity assay. As expected, HEK293-TYR cells expressed TYR, but not TRP1 and TRP2, whereas HEMs expressed all these melanogenic enzymes (Figure 6(a)). The TYR expressed in HEMs appeared mostly as the fully mature form (~80 kDa), and the TYR expressed in HEK293-TYR cells appeared as a mixture of mature and immature forms (Figure 6(a)). The TYRs expressed in HEK293-TYR and HEMs exhibited similar catalytic activities (Figure 6(b)). In addition, each of resveratrol, p-coumaric acid, and arbutin exhibited similar inhibition patterns against TYRs expressed in those two different cell types (Figures 5(a) and 6(c)). These results support the molecular similarity between TYRs expressed in HEK293-TYR cells and HEMs.

The bioactivities of resveratrol and p-coumaric acid were compared in HEMs. Cells were treated with 1.0 mM L-tyrosine (substrate) in the absence or presence of test material (inhibitor) at the indicated concentrations. This treatment was then repeated every other day for 6 days. As shown in Figure 7(a), treatment of HEMs with L-tyrosine increased intracellular melanin contents, and this melanin synthesis was dose dependently attenuated by resveratrol and p-coumaric acid (Figure 7(b)). Resveratrol was found to be slightly more effective than p-coumaric acid at inhibiting melanin synthesis. Repeated treatment of resveratrol above 10 µM caused cytotoxicity whereas p-coumaric acid had only a little cytotoxic effect at 100 µM (Figure 7(c)).

4. Discussion

The present study shows that resveratrol is a highly potent and selective inhibitor of human TYR. A literature search indicated that opinions differ regarding the effects of resveratrol on TYR activity. Discrepancies between experimental results seem to be associated with different enzyme sources (human, murine, or mushroom).

Resveratrol is oxidized by mushroom TYR and becomes a suicide inhibitor [2628]. However its potency as a mushroom TYR inhibitor was determined to be very low (Figure 5(c)) compared to its potency as a human or murine TYR inhibitor (Figures 5(a) and 5(b)).

Kim et al. [29] reported that resveratrol inhibited murine TYR weakly (32.7% inhibition at 100 µM or 22.8 µg mL−1), but Yanagihara et al. [30] reported that it is a potent inhibitor (  µg mL−1). Only the latter study showed a dose-response curve and is, though, more reliable. As observed in the present study, resveratrol produces insoluble precipitate at high concentrations, making the assay inaccurate. Thus, data from the assay at a single high concentration may be erratic. In the present study, the IC50 value of resveratrol against murine TYR was estimated to be 4.3 µM (1.0 µg mL−1) from a dose-response curve at low concentration range unaffected by solubility problem (Figure 5(b)).

Newton et al. [31] reported that resveratrol inhibited human TYR activity by ca. 75% at 20 µg mL−1 in the assay using the lysates of HEMs. In our assay using the lysates of HEK293-TYR cells and HEMs, resveratrol was observed to inhibit human TYR activity by 80~90% at 10~30 µg mL−1 (Figures 5(a) and 6(c)). The IC50 values of resveratrol against human TYR activity were determined to be 1.7 µM (0.39 µg mL−1) with the lysates of HEK293-TYR cells (Figure 5(a)) and 5.3 µM (1.2 µg mL−1) with the lysates of HEMs (Figure 6(c)). Thus, the data from these studies consistently indicate that resveratrol is a potent inhibitor against human TYR.

Resveratrol has been previously shown to inhibit melanin synthesis in murine melanoma B16/F10 cells [28, 30] and HEMs [31, 32]. Based on our observation that resveratrol inhibits murine and human TYR potently, we are of the opinion that resveratrol might attenuate melanin synthesis through inhibition of TYR activity. Of course, other mechanisms could be involved in the inhibition of melanin synthesis by resveratrol. For example, resveratrol may regulate the posttranslational maturation of melanogenic enzymes in HEMs [31].

Previously, we have found that p-coumaric acid is a much stronger inhibitor of human TYR than kojic acid, arbutin [18], and various phenylpropanoids [19]. In the present study, resveratrol was found to be an even more potent inhibitor of human TYR than p-coumaric acid. In our bioassay using HEMs, resveratrol was also found to reduce melanin synthesis more effectively than p-coumaric acid (Figure 7(b)). However, resveratrol appeared to be slightly more cytotoxic than p-coumaric acid (Figure 7(c)). The mechanism of this cytotoxic effect of resveratrol is currently unclear but it could be an artifact due to culture conditions, because resveratrol is rapidly oxidized in carbonate-containing culture medium producing hydrogen peroxide [33]. Further studies are needed to evaluate the comparative efficacies and safeties of these two naturally occurring human TYR inhibitors in vivo.

In the present study, resveratrol was found to be the main active constituent of VVC (Figure 2), the ethanolic extract of which inhibited human TYR activity potently (Figure 1). VVC is the dried stems of the grape tree (Vitis vinifera L.) belonging to Vitaceae. The polyphenolic composition and bioactivities of grape seed extracts have been extensively studied [34]. In contrast, grape stems have been barely investigated in this context. The present study shows that VVC is a useful source of resveratrol (Figure 4). Because resveratrol was found to be a potent inhibitor of human TYR and cellular melanogenesis, extracts of VVC containing resveratrol would be useful as skin whitening agents. The extract of Mori Ramulus (twigs of Morus alba L.) was also considered to be potentially useful as a skin whitening agent because it inhibited both mushroom and human TYR strongly (Figure 1). Indeed, previous studies have demonstrated its inhibitory effects against skin pigmentation in animal models [35]. Oxyresveratrol and mulberroside A have been proposed as active constituents [35, 36]. Further studies are needed to compare the human skin whitening effects of VVC and Mori Ramulus extracts.

HEK293-TYR cells are a useful source of human TYR needed in screening assays for melanogenesis inhibitors or skin whitening agents. HEK293-TYR cells constitutively and robustly express catalytically active human TYR and proliferate rapidly in relatively inexpensive culture media. This is a considerable advantage because HEMs grow slowly in expensive media. In addition, as compared with HEMs that expressed all melanogenic enzymes, HEK293-TYR cells overexpressed TYR only (Figure 6(a)). Thus, the cell lysates of HEK293-TYR cells are more suitable for TYR-specific assays, and their use makes data interpretation more straightforward. Overall, using HEK293-TYR cells, we were able to test many samples in a reasonable time at low cost.

5. Conclusion

The present study shows that resveratrol is the main active compound in VVC responsible for the inhibition of human TYR activity. The use of HEK293-TYR cells enabled effective screening of plant sources and allowed us to resolve previously controversial observations regarding the effects of resveratrol on TYR activity and melanin synthesis. Furthermore, resveratrol was found to reduce melanin synthesis in HEMs at subtoxic concentrations. The findings of this study suggest that resveratrol and resveratrol-containing extracts of VVC have potential as skin whitening agents.


This study was supported by a Grant of the Korea Health technology R&D Project, Ministry of Health and Welfare (Grant no. A111345, A103017) and by the Regional Technology Innovation Program of the Ministry of Knowledge Economy, Republic of Korea (Grant no. RTI 04-01-01).


  1. G. E. Costin and V. J. Hearing, “Human skin pigmentation: melanocytes modulate skin color in response to stress,” The FASEB Journal, vol. 21, no. 4, pp. 976–994, 2007. View at: Publisher Site | Google Scholar
  2. J. H. Epstein, “Photocarcinogenesis, skin cancer, and aging,” Journal of the American Academy of Dermatology, vol. 9, no. 4, pp. 487–502, 1983. View at: Google Scholar
  3. J. A. D'Orazio, T. Nobuhisa, R. Cui et al., “Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning,” Nature, vol. 443, no. 7109, pp. 340–344, 2006. View at: Google Scholar
  4. Y. Yamaguchi, J. Z. Beer, and V. J. Hearing, “Melanin mediated apoptosis of epidermal cells damaged by ultraviolet radiation: factors influencing the incidence of skin cancer,” Archives of Dermatological Research, vol. 300, supplement 1, pp. S43–S50, 2008. View at: Publisher Site | Google Scholar
  5. J. Cabanes, S. Chazarra, and F. Garcia-Carmona, “Kojic acid, a cosmetic skin whitening agent, is a slow-binding inhibitor of catecholase activity of tyrosinase,” Journal of Pharmacy and Pharmacology, vol. 46, no. 12, pp. 982–985, 1994. View at: Google Scholar
  6. K. Maeda and M. Fukuda, “Arbutin: mechanism of its depigmenting action in human melanocyte culture,” Journal of Pharmacology and Experimental Therapeutics, vol. 276, no. 2, pp. 765–769, 1996. View at: Google Scholar
  7. M. V. Schiaffino, “Signaling pathways in melanosome biogenesis and pathology,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 7, pp. 1094–1104, 2010. View at: Publisher Site | Google Scholar
  8. C. Olivares and F. Solano, “New insights into the active site structure and catalytic mechanism of tyrosinase and its related proteins,” Pigment Cell and Melanoma Research, vol. 22, no. 6, pp. 750–760, 2009. View at: Publisher Site | Google Scholar
  9. G. Cardinali, S. Ceccarelli, D. Kovacs et al., “Keratinocyte growth factor promotes melanosome transfer to keratinocytes,” Journal of Investigative Dermatology, vol. 125, no. 6, pp. 1190–1199, 2005. View at: Publisher Site | Google Scholar
  10. F. Solano, S. Briganti, M. Picardo, and G. Ghanem, “Hypopigmenting agents: an updated review on biological, chemical and clinical aspects,” Pigment Cell Research, vol. 19, no. 6, pp. 550–571, 2006. View at: Publisher Site | Google Scholar
  11. S. M. Anu, H. J. Kim, J. E. Kim, and Y. C. Boo, “Flavonoids, taxifolin and luteolin attenuate cellular melanogenesis despite increasing tyrosinase protein levels,” Phytotherapy Research, vol. 22, no. 9, pp. 1200–1207, 2008. View at: Publisher Site | Google Scholar
  12. J. K. Hyo, M. A. Sang, and C. B. Yong, “A dual mechanism of 4-hydroxy-5-methyl-3[2H]-furanone inhibiting cellular melanogenesis,” Journal of Cosmetic Science, vol. 59, no. 2, pp. 117–125, 2008. View at: Google Scholar
  13. Y. J. Kim and H. Uyama, “Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future,” Cellular and Molecular Life Sciences, vol. 62, no. 15, pp. 1707–1723, 2005. View at: Publisher Site | Google Scholar
  14. T. S. Chang, “An updated review of tyrosinase inhibitors,” International Journal of Molecular Sciences, vol. 10, no. 6, pp. 2440–2475, 2009. View at: Publisher Site | Google Scholar
  15. B. S. Kwon, A. K. Haq, S. H. Pomerantz, and R. Halaban, “Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7473–7477, 1987. View at: Google Scholar
  16. H. J. Wichers, K. Recourt, M. Hendriks et al., “Cloning, expression and characterisation of two tyrosinase cDNAs from Agaricus bisporus,” Applied Microbiology and Biotechnology, vol. 61, no. 4, pp. 336–341, 2003. View at: Google Scholar
  17. K. Takara, H. Iwasaki, K. Ujihara, and K. Wada, “Human tyrosinase inhibitor in rum distillate wastewater,” Journal of Oleo Science, vol. 57, no. 3, pp. 191–196, 2008. View at: Google Scholar
  18. S. M. An, J. S. Koh, and Y. C. Boo, “p-coumaric acid not only inhibits human tyrosinase activity in vitro but also melanogenesis in cells exposed to UVB,” Phytotherapy Research, vol. 24, no. 8, pp. 1175–1180, 2010. View at: Publisher Site | Google Scholar
  19. M. Kim, S. M. An, J. S. Koh, D. I. Jang, and Y. C. Boo, “Use of non-melanocytic HEK293 cells stably expressing human tyrosinase for the screening of anti-melanogenic agents,” Journal of Cosmetic Science, vol. 62, no. 5, pp. 515–523, 2011. View at: Google Scholar
  20. M. Kim, J. Park, K. Song, H. G. Kim, J. S. Koh, and Y. C. Boo, “Screening of plant extracts for human tyrosinase inhibiting effects,” International Journal of Cosmetic Science, vol. 34, no. 2, pp. 202–208, 2012. View at: Publisher Site | Google Scholar
  21. S. M. An, J. S. Koh, and Y. C. Boo, “Inhibition of melanogenesis by tyrosinase siRNA in human melanocytes,” BMB Reports, vol. 42, no. 3, pp. 178–183, 2009. View at: Google Scholar
  22. H. S. Lee, B. W. Lee, M. R. Kim, and J. G. Jun, “Syntheses of resveratrol and its hydroxylated derivatives as radical scavenger and tyrosinase inhibitor,” Bulletin of the Korean Chemical Society, vol. 31, no. 4, pp. 971–975, 2010. View at: Publisher Site | Google Scholar
  23. S. M. An, S. I. Lee, S. W. Choi, S. W. Moon, and Y. C. Boo, “p-Coumaric acid, a constituent of Sasa quelpaertensis Nakai, inhibits cellular melanogenesis stimulated by α-melanocyte stimulating hormone,” British Journal of Dermatology, vol. 159, no. 2, pp. 292–299, 2008. View at: Publisher Site | Google Scholar
  24. H. Y. Park, M. Kosmadaki, M. Yaar, and B. A. Gilchrest, “Cellular mechanisms regulating human melanogenesis,” Cellular and Molecular Life Sciences, vol. 66, no. 9, pp. 1493–1506, 2009. View at: Publisher Site | Google Scholar
  25. N. Branza-Nichita, G. Negroiu, A. J. Petrescu et al., “Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 8169–8175, 2000. View at: Publisher Site | Google Scholar
  26. P. Bernard and J. Y. Berthon, “Resveratrol: an original mechanism on tyrosinase inhibition,” International Journal of Cosmetic Science, vol. 22, no. 3, pp. 219–226, 2000. View at: Publisher Site | Google Scholar
  27. A. G. Gonzalvez, A. Gonzalez Urena, R. J. Lewis, and G. van der Zwan, “Spectroscopy and kinetics of tyrosinase catalyzed trans-resveratrol oxidation,” The Journal of Physical Chemistry B, vol. 116, no. 8, pp. 2553–2560, 2012. View at: Publisher Site | Google Scholar
  28. H. Satooka and I. Kubo, “Resveratrol as a kcat type inhibitor for tyrosinase: potentiated melanogenesis inhibitor,” Bioorganic & Medicinal Chemistry, vol. 20, no. 2, pp. 1090–1099, 2012. View at: Publisher Site | Google Scholar
  29. Y. M. Kim, J. Yun, C. K. Lee, H. Lee, K. R. Min, and Y. Kim, “Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 16340–16344, 2002. View at: Publisher Site | Google Scholar
  30. M. Yanagihara, M. Yoshimatsu, A. Inoue, T. Kanno, T. Tatefuji, and K. Hashimoto, “Inhibitory effect of gnetin C, a resveratrol dimer from melinjo (Gnetum gnemon), on tyrosinase activity and melanin biosynthesis,” Biological and Pharmaceutical Bulletin, vol. 35, no. 6, pp. 993–996, 2012. View at: Publisher Site | Google Scholar
  31. R. A. Newton, A. L. Cook, D. W. Roberts, J. H. Leonard, and R. A. Sturm, “Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes,” Journal of Investigative Dermatology, vol. 127, no. 9, pp. 2216–2227, 2007. View at: Publisher Site | Google Scholar
  32. S. Y. Kim, K. C. Park, S. B. Kwon, and D. S. Kim, “Hypopigmentary effects of 4-n-butylresorcinol and resveratrol in combination,” Pharmazie, vol. 67, no. 6, pp. 542–546, 2012. View at: Google Scholar
  33. N. C. Yang, C. H. Lee, and T. Y. Song, “Evaluation of resveratrol oxidation in vitro and the crucial role of bicarbonate ions,” Bioscience, Biotechnology and Biochemistry, vol. 74, no. 1, pp. 63–68, 2010. View at: Publisher Site | Google Scholar
  34. M. Nassiri-Asl and H. Hosseinzadeh, “Review of the pharmacological effects of Vitis vinifera (grape) and its bioactive compounds,” Phytotherapy Research, vol. 23, no. 9, pp. 1197–1204, 2009. View at: Publisher Site | Google Scholar
  35. K. T. Lee, K. S. Lee, J. H. Jeong, B. K. Jo, M. Y. Heo, and H. P. Kim, “Inhibitory effects of Ramulus mori extracts on melanogenesis,” Journal of Cosmetic Science, vol. 54, no. 2, pp. 133–142, 2003. View at: Google Scholar
  36. K. T. Park, J. K. Kim, D. Hwang, Y. Yoo, and Y. H. Lim, “Inhibitory effect of mulberroside A and its derivatives on melanogenesis induced by ultraviolet B irradiation,” Food and Chemical Toxicology, vol. 49, no. 12, pp. 3038–3045, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Jiaa Park and Yong Chool Boo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.